BEIJING, Nov 18 (Alliance News): The 11th Cell Biology Industry Conference (CBIC) commenced in Beijing, drawing over 3,000 attendees from clinical research institutions, hospitals, universities, biotechnology companies, and investment groups.
The conference highlighted key areas of innovation, including cell therapy, organoid drug development, precision medicine, stem cell industrialization, and extracellular vesicle research.
The discussions aligned with China’s 2024 government agenda to enhance biosciences such as gene editing, cell technology, and synthetic biology, as reported by China Economic Net (CEN).
In a significant milestone, Beijing recently released the world’s first international standard for stem cell data management, ISO 8472-1:2024, developed collaboratively by experts from multiple countries, including China, Japan, and the United States.
Cell therapy, often referred to as the third revolution in medical history, has seen remarkable growth in China.
The market size for China’s cell health industry reached 14.2 billion yuan in 2023 and is projected to skyrocket to 174.5 billion yuan by 2032, with an annual growth rate of 32.1%, surpassing the global average.
Notably, advancements in immune cell therapy, particularly CAR-T technology, have been groundbreaking. Since the introduction of China’s first CAR-T product in 2021, six CAR-T therapies have been approved, accounting for over 50% of global CAR-T products.
Last month, Chinese researchers unveiled a new generation of universal CAR-T cells in Nature, leveraging CRISPR-Cas9 technology to reduce costs and waiting times for patients.
China is rapidly becoming a global leader in biotechnology, ranking second worldwide in cell therapy clinical trials, behind only the United States. Over the past decade, the number of registered cell medicine companies in China surged to 33,000 in 2023, marking a record high.
The CBIC underscores China’s commitment to advancing cell biology and its potential to transform healthcare globally.
